Plain-English translation of NCT06518837 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that helps people lose weight, in patients being treated for early-stage hormone receptor-positive, HER2-negative breast cancer. The study wants to see if losing weight with this medication during cancer treatment is safe and helpful, and whether it might affect how well the cancer stays away long-term. Researchers will track weight loss, side effects, and several health markers over the course of the study.
People with breast cancer who are overweight or obese may have different outcomes than others. This study explores whether helping patients lose weight during cancer treatment could be both safe and beneficial, and whether the medication affects cancer recurrence risk.
You likely qualify if…
You likely don't qualify if…
You would receive weekly injections of the medication under your skin in your stomach, upper arm, or thigh, rotating injection sites each week. The dose starts low and increases gradually over several weeks to find the right amount for you. Throughout the study, you'll have regular clinic visits for weight measurements, blood work to check your health markers, heart function tests, and quality-of-life assessments. The study also monitors for signs of cancer recurrence over three years using blood tests and imaging as appropriate.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States